Plasticell has teamed up with encapsulation and screening tech firm Sphere Fluidics to develop genetic modification technology for cell therapy production.
TxCell is working on new ways of delivering its Crohn's disease therapy Ovasave that will replace the somewhat unusual method it is using in clinical trials.
CSL Behring has opted to extend the half-life of its haemophilia B treatment Idelvion using a technology developed by Novozymes A/S subsidiary Albumedix.
BioPharmaSpec has set up business development teams for the Indian and Asia-Pacific markets and predicted increased demand for biosimilar characterisation services.
The combination of Gyros and Protein Technologies will give biomanufacturers greater access to protein and peptide processing tools and reagents, the CEO says.
Sanofi Pasteur, the vaccines division of Sanofi, has launched a vaccine research and development project targeting the prevention of Zika virus infection and disease.
New facilities and a successful CMO tech transfer have helped turnaround the manufacturing of cell therapy product Ovasave, says TxCell after production was suspended last year.
Industrial microorganism design firm Ginkgo Bioworks expects to cut six months off development timelines using mini-bioreactor technology supplied by Sartorius Stedim Biotech (SSB).
WuXi Biologics and Prima BioMed have announced that the first dose of a Chinese-manufactured biologic has been dosed in a clinical trial in the European Union.
A tarantula venom toxin that inhibits a novel pain receptor will guide development of more effective non-opioid painkillers say researchers in Australia.
Sanofi will tap Japanese academics' personalised medicine knowhow under a new collaboration with the University of Tokyo's translational research initiative (TR).
Unchained Labs has acquired Freeslate, a provider of high-throughput solutions for biologics formulation development and small molecule chemistry – marking the company’s 4th acquisition in 12 months.
Japanese researchers have developed a peptide vaccine with the potential to protect the brain when administered prior to a stroke, according to a study presented at the American Stroke Association’s International Stroke Conference.
Dutch biotech company, Micreos, announced yesterday that it has secured €12 million in funding for the clinical development of its antibacterial lysin technology, Staphefekt.
Silicon Biosystems Menarini and Macrogen announced they will form a partnership to provide clinical assays and new procedures for precision medicine in cancer.
Reliance on third-party technologies is leaving T-Cell drug developers vulnerable and has driven the larger players to invest in their own platforms, say experts.
Repositive has secured funding to develop a premium version of its gene data collaboration platform for personalised medicine and rare disease researchers.
The US NIAID is supporting development of several experimental Zika vaccines but none will be ready before Brazil, the country at the centre of the current outbreak, hosts the Olympic Games this summer.
Mucosis has been awarded a Wellcome Trust grant of €3.7m ($4m) to help develop a Respiratory Syncytial Virus (RSV) vaccine using its intranasal delivery platform.
Beijing-based Sinobioway and US biotech company BioAtla have selected the first conditionally active biologics (CABs) they will work on under a co-development deal.
Pfizer has invested $46m in separate collaborations with four R&D companies specialising in developing ADCs, immuno-oncology candidates and gene-therapies.
Roche has collaborated with CDMO Catalent to access the SMARTag protein-modification and conjugation technology in a deal that could be worth up to $618m (€568m).
Newly private WuXi AppTec has announced plans to invest $120m in a biopharmaceutical development laboratory and clinical-scale manufacturing facility in Shanghai, China.
The Cell Therapy Catapult (CTC) UK is in talks over gene and cell therapy partnerships similar to its latest deal with Cancer Research Technology and the University of Birmingham, says Chief Business Officer Matthew Durdy.
